The experimental drug in the early stages of development of aggressive brain tumors can cross the blood-brain barrier of the tumor, destroy tumor cells and block the growth of blood vessels of the tumor, according to the Internet publication for girls and women from 14 to 35 years old Pannochka. net This conclusion came as a result of a study led by specialists from the Comprehensive Cancer Center at Ohio State University, Arthur G's cancer hospital. James and the Richard J Research Institute. Solovy.

The results of the work were published in a recent issue of the journal Molecular Therapy.

Laboratory tests and animal studies have shown how an agent, called SAPC-DOPS, targets tumor cells and blood vessels. These data support the further development of the drug as a new treatment for brain tumors.

Multiform glioblastoma is the most common and aggressive form of brain cancer, with a median survival of about 15 months. The main obstacle to improving the treatment of 3,470 cases that are expected in the US this year is the blood-brain barrier.

This term refers to the region of closely fitting cells constituting the blood vessels of the brain. This barrier protects the brain from the toxins of blood, but it keeps the drugs from reaching the tumor.

"Few drugs have the ability to cross the blood-brain barrier of the tumor and reach the right cells," says principal researcher Balveen Kaur, Ph.D., associate professor of neurologic surgery and head of the laboratory of neurological sciences Dardinger. "Our preclinical studies show that SAPC-DOPS does both, inhibiting the growth of new blood vessels of the tumor. This gives hope that this agent can one day become an important assistant in the treatment of glioblastoma and other solid tumors ".

SAPC-DOPS (saposin dioleoylphosphatidylserine-C) is a nanopreparation that, in preclinical studies, showed activity in glioblastoma, pancreatic cancer and other solid tumors. Nanovezules unite tumor cells, causing their elimination by apoptosis.

Main findings of the study:.

SAPC-DOPS binds to open areas (PtdSer) on the surface of tumor cells;.

Blocking PtdSer on cells prevents tumor targeting;.

SAPC-DOPS inhibits the growth of tumor blood vessels in cells and in animal experiments, probably because these cells are also exposed to a high level of exposure to PtdSer.

Hypoxic cells are sensitive to SAPC-DOPS.

"Based on our data, we assume that SAPC-DOPS can have a synergistic effect in combination with chemotherapy or radiation therapy, which are known to increase the level of exposure of PtdSer to cancer cells," Kaur says..

medbe. en.

Keywords:.